Molecular Partners Presents MP0712 Data at Two Conferences
The DLL3-targeting Radio-DARPin is set to feature in oral and poster presentations at SNMMI and NACLC later this year.
Updated on Nov. 5, 2026 in Cancer
Molecular Partners AG announced presentations on its lead medicine MP0712 at the 2026 SNMMI Theranostics Conference and the IASLC/ASCO NACLC 2026 meeting. MP0712 is a DLL3-targeting Radio-DARPin co-developed with Orano Med.
Why it matters
The presentations will share clinical and scientific data on a therapy in a Phase 1/2a study for small cell lung cancer and other neuroendocrine cancers. Public disclosure of dose escalation findings helps clinicians and researchers track early-stage progress in targeted radiotherapy.
The NACLC poster reports initial dose escalation data from a first-in-human Phase 1/2a study of [212Pb]Pb-MP0712 (registry NCT07278479), but the stub does not disclose response rates or safety figures. Those results are not yet public, and the full data will only be available once the presentations are delivered.
The players
Molecular Partners AG
A clinical-stage biotech company founded in 2004 that develops DARPin therapeutics, with offices in Zurich, Switzerland and Concord, Massachusetts.
Orano Med
The radiopharmaceutical company that co-develops MP0712 with Molecular Partners.
Daniel Steiner, Ph.D.
A Molecular Partners scientist presenting on target expression thresholds at the SNMMI Theranostics Conference.
Ticiana Leal, M.D.
The presenting author of the MP0712 poster at NACLC 2026, based at an Atlanta, Georgia institution.
The details
Daniel Steiner, Ph.D., will give a 20-minute oral presentation titled 'How much Target Expression is Enough?' at the SNMMI session on Future of Theranostics. Ticiana Leal, M.D., is the presenting author of a poster on [212Pb]Pb-MP0712 reporting initial dose escalation results at NACLC 2026.
Timeline
November 7, 2026, 8:40-9:00 am EST: Daniel Steiner's oral presentation at the SNMMI Theranostics Conference in Bethesda, Maryland.
December 5, 2026, 4:15-5:45 pm MST: Ticiana Leal's poster session at NACLC 2026 in Scottsdale, Arizona.
Pipeline Context
MP0712 extends Molecular Partners' DARPin platform, founded in 2004, into radiopharmaceutical targeting of DLL3 in neuroendocrine cancers. The company's clinical progress is measured through its Phase 1/2a program rather than approved products.
For patients with small cell lung cancer or other neuroendocrine tumors, the trials described here are one of the investigational options being tested in clinical studies. Eligibility and access depend on enrollment in the Phase 1/2a study and are not established by these presentations.
The takeaway
Early dose escalation data for targeted radiotherapies helps define safe dosing before larger trials begin. Readers tracking cancer drug development can watch for the full data when the presentations are released.
What happens next
Molecular Partners will make the SNMMI and NACLC presentations available on its website after each session.
Further reading
Explore more cancer research and treatment news to see how targeted radiotherapies fit into the broader field.
More information
Presentations will be posted on the Molecular Partners website after each conference.
